RxDoctor Payments Data

Jared Williams, MD

Family Medicine · Costa Mesa, CANPI 1568401057

Payments from drug & device makers

$1,746in general payments, 2019–2025

Across 57 payments — averaging $30.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$624
  • Lilly USA, LLC$236
  • Takeda Pharmaceuticals U.S.A., Inc.$199
  • Novo Nordisk$141
  • Teva Pharmaceuticals USA, Inc.$125
  • Merck$119
  • plus $303 from 8 others

What the payments were for

  • Food & beverage$1,746100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,746 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$38,062
Medicare patients
194
Services billed
458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$62,505
EliquisApixaban56$53,194
MounjaroTirzepatide35$49,322
TrulicityDulaglutide30$43,461
JanuviaSitagliptin Phosphate38$41,651
FarxigaDapagliflozin Propanediol29$34,560
XareltoRivaroxaban29$30,220
Depakote ErDivalproex Sodium12$19,307
TopamaxTopiramate14$16,766
LinzessLinaclotide19$16,371
JardianceEmpagliflozin21$12,745
TrintellixVortioxetine Hydrobromide23$10,842
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,164
SymbicortBudesonide/Formoterol Fumarate13$6,541
VyvanseLisdexamfetamine Dimesylate15$6,027

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$236$92,78365 claims
Novo NordiskOzempic$141$62,50565 claims
PfizerEliquis$15$53,19456 claims
MerckJanuvia$119$41,65138 claims
AstraZenecaFarxiga, Symbicort$23$41,10142 claims
AbbVieLinzess, Synthroid$624$21,91771 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$199$16,86938 claims
GSKTrelegy Ellipta$21$7,16411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Costa Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →